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(s7) ABSTRACT
The invention relates to the Íield of medicine. In paÍicular, it
rclatcs to recombinant cationic polypeptides and their use as
biolubricant. Provided is a biolubricant substance comprising
the amino acid sequence[(CKGvP)9]", wherein n is >5.
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I]ACKGROUND OF THE INVENTION
Thc invcntion relates to the field of medicine. In particular,
it relates to rccombinant cationic polypeptides and their use
as biolubricant,
Biomacromolecules do not only fulfil complex functions
insidc thc cell or within membranes, but proteinaceous mate-
rials may also play a very criícal role at interfaces. One such
examplc is biolubrication, where sliding surfaces coatcd with
synthetic polymers and biological building blocks have been
intensively investigated.lr I Biolubrication is an essential fea-
ture of hcalth and can become impaired in the elderly or
diseascd.12l Sjógren's syndrome, for instance, is a disease
causing a variety_ of symptoms like dry eyes,l3l dry mouth,lal
vaginal drynesslsl and excessive friction and wearat the knee
and hip joints.lól
Biolubrication is mediated by gtandular secretions con-
taining (glyco-) proteins that adsorb at the sliding interface
and tbrm a conditioning film. Although water forms the basis
of all biolubrication phenomena, it is easily removed from in
betwecn sliding surfaces during physiological activities asso-
ciated with high contact pressures. To counter this, condition-
and protects against wear due to erosionÍ I ol and abrasion.l I I I
. 
Maintcnurce of adequate biolubrication in the oral cavity
ts not only challenged by disease and aging, but also by high
contact prcssures. Contact pressures on molar surfaces during
mastication can be as high as 86 MPal t2l which is one order of
magnitudc higher than the pressures experienced in hip and
knee joints.l r3l This load makes the maintenance and resro-
rarion of lubrication more challenging in the oral cavity than
in othcr parts ofthe human body where articulating surfaces
are involvcd.
Disordcrs a.ssociated with reduced or impaired biolubrica-
tion includc xerostomia. Xerostomia refórs to drv mouth
eused by a lrrck of saliva and is often associated with some
form of salivary gland dysfunction. In the field of oral care,
xÊrostomia is problematic as saliva provides a protective
the tceth or allowing an accumulation of harmful
bod particles can lead to bad breath (halitosis) or
us 9,334,312 B2
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mon in elderly people. Amongst diseases causing
xerophthalmia are found: vitamin A deficit, Sjógren syn-
drome, rhcumatoid arthritis and <lther rheumatologic dis-
eases, chemical or thermal burns, drugs such as atcnolol,
5 chlorpheniramine, hydrochlorothiazide, isotretinoin, ketoro-
lac, ketotifen, Ievocabastin, lcvofloxacin, oxybutynin,
tolterodine.
Recognizing the need for an improved approach to restorc
. ^  or enhance biolubrication, e.g. in the treatment of xerostomiaI 0 
or xerophthalmia, the present invcntors set out to devclop ncw
biolubricants. In particular, they aimed at providing a biolu-
bricant system that does not involve the administration of
heterologous or aÍtificial material e.g. in a bodily cavity, but
,, 
which relies on strengthening the cxisting, though oltcn
impaired, endogenous conditioning fi Im.
DESCRIMON OF TTIE INVENTION
zo It was found that the above goals could be met by thc
provision of non-toxic, superchargcd proteins having a spc-
cific cationic repeat unit of five amino acids, containing thc
aliphatic residues glycine (G), valine (V), proline (P) and
positively charged lysine (K). Using salivary lubrication as
25 test bed we show that these non-toxic, cationic, rccombinant
proteins with certain minimum positive charges works in
concert with the existing lubrication system e.g. in thc oral
cavity. These proteins restore and enhance oral lubrication by
first rigidifying the existing conditioning layer and thcn
:o recruiting large glycoproteins (e.g. mucins) which help in
Iubrication and keeping the surfaces hydrated, thus decreas-
ing the discomfort during speech, mastication and swallow-
ing in addition to the general dry Í'eeling. For the patients
where the salivary glands are partly impaired the non-toxic,
ls supercharged protein will strengthen the existing salivary
conditioning film and cause preferential recruitment of
mucins and improve thc lubrication and hydration feeling in
the mouth. For patients where the salivary glands are com-
pletely impaired, this protein along with heterologous mucins
c0 will do the job. This would improve the quality of patient lifc,
who are sutïering from either the Sjógren's syndrome or loss
of salivary secretions due to radiation therapy around the
Maxillofacial region.
Thus, not only can cationic supercharged, unfolded
as polypeptides (SUPs) ofthe invention interact with the nega-
tively charged, naturally occurring mucins, they also possess
significantly lower cytotoxicity than other cationic polyelec-
trolytes commonly used in biomedical applications. More-
over, they are well-defined with respect to their length, com-
50 position and charge density and are broken down into non-
toxic, naturally occurring amino-acids upon digestion. Our
strategy requires only small amounts of proteins which work
in concert with the existing lubrication mechanism in the oral
cavity. No existing commercial product uses this stÍategy.
55 Accordingly, theinventionprovides aproteinaceous biolu-
bricant substance comprising the amino acid sequencc
[(GKGVPXSEQ ID NO:l)o]n wherein n is >-5. In a relared
aspect, thcre is provided a substance comprising the gencral
formula Head-[(cVcVPXSEQ lD NO: 2XGKGVPXSEQ lD
60 NO: l).rln-Thil, wherein n is à5: Head is an amino acid
sequence of at lcast 3 amino acids and Tail is zrn amino acid
sequence of at least 3 amino acids, and the usc thereof as
biolubricant.
Biolubricant substanccs of the invention is herein also
os referred to as "supercharged, unfoldcd polypcptides", abbrc-
viated as SUPs. A cationic SUP of thc invention is charactcr-
izedby a repcating amino acid sequcncc which is based on a
;pftêct on thc teeth and can dilute or wash away harmful
àocteria and/or food particles from the oral cavity. Failure to
seriously, to infections of the mucosal or periodontal
tlf thc oral cavitv.
Often, oral dryness is due to insufficient retention of water
rculcs in adsorbed SCFs due to low salivary flow rates (< I
min-') or dysfunction of a particular saiinury gland.l2l
tts suÍïering from oral dryness symptoms are treated
artiíicial salivas, often containing lubricants like pig
ic, mucins, polyacrylic acid and caóoxymethyl cellu-
""''"r However, artificial salivas only yield temporary
in patients, as the adsorbed conditioning films are
to sufliciently retain water due to lack of structural
disease associated with impaired biolubrication is
syndrome or xerophthalmia. Xerophthalmia is a mul-
discase ofthe tears and ocular surface that results in
of discomfort, visual disturbance, and tears film
with potential damage to the oculaÍ surface. Mul-
can lead to xerophthalmia, which is more com-
us 9,334,31282
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motif found in elastin. Genetically engineored proteins com-
prising elastin-like blocks and their use as mucoadhesive are
known in the art.
For example, US 2W510196440 discloses various
examples of repetitive amino acid sequences derived from, 5
among others, elastin. Specifically disclosed is the elastin-
like protein comprising the motif ITPGVGXSEQ ID NO:
4)+1".
U52W810226706 relates to personal care compositions
comprising a bioactively effective amount of à repeat l0
sequence pÍotein polymer. Disclosed is a silk-elastin polymer
SELP4TK consisting exclusively of silk-like crystalline
blocks and elastin-like flexible blocks. The silk repeating
sequence units are used to impalt durability and the elastin- 
,,like repeating sequence units are used to impart flexibility to 
--
the copolymer. SEQ ID NO:19 of US2OO8|O226706 contains
886 residues, among which the cationic sequence GKGVP
(SEQ ID NO: l). However, the remainder of the sequence
consists of non-charged silk-like units having the sequence 26
CAGAGS (SEQ ID NO: 7). As a result, a subsrance of
U52W810226706 has far less cationic charges than a super-
charged substance cll'the invention, which is devoid of silk-
like motifs and furthermore contains a high number of equi-
distant Lysine residues. This ha.s the advantage of providing a z-s
highly charged peptide having a low charge density. The low
charge density ensures that a SUP of the invention is non-
toxic, and can thus be safely used in vivo.
As said, a biolubricant substance according to the invention
is charácterized by the presence of at least five repeated units go
having the sequence I(GKGVPXSEQ ID NO: l)rl. This was
tbund to have a clear effect on stiffening the basal SCF and
decreasing the coefficient offraction (COF).
Prefcrably however, the substance has an cven higher car
ionic charge such that more negatively charged mucins can be 35
absorbed. In one embodiment, the invention provides a biolu-
bricant substancc comprising the formula I(GKCVPXSEQ
ID NO: I ).rln, wherein n is >6, preferably >7, more preferably
>8. For example, very good results were obtained with the
SUP rcferred hercin below to as "K72", comprising 72 no
charged lysines. Thc upper value ofn is not critical to achieve
the desired biolubricant effect. However, very large polypep-
tides are less preferred in view of their manufacture and/or
purification. Typically, the value ofn is up to 30, preferably up
to 20. In one embodiment, n is an integer in the range of 5-2O, qs
l ike 6-18 or 8-14.
A biolubricant substance according to tht: invention can
have a linear structure or a branched structure. Linear struc-
tures allow for the manufacture ofa nucleic acid encoding the
biolubricant polypeptide, and are thercfore preferred in case so
the substance is prepared by recombinant cxpression. The
biolubricant substance may, in addition to the cationic repeat
sequence, comprise an N- and./or C-terminal extension. These
may facilitate one or more steps during the (recombinant)
manufacture of the subsLance .g. cloning, expression, puri- ss
fication. In a specific embodiment, the cationic pentapeptide
repeat sequence is preceded by the sequencc CVGVP(SEQ
ID NO: 2).Hence, the invention also relates to a biolubricant
substance comprising the sequcnce I(GVGVPXSEQ ID NO:
2XCKGVPXSEQ ID NO: l)rl" wherein n is >5, preferably oo
)6, more preferably >7.
Still lurther, the repcat sequence is flanked by a Head and
a Tail scquence, thus providing a biolubricant of the general
formula Head-[(cVGVP)(SEQ ID NO: 2XcKGVPXSEe il)
NO: l)ul,-Tail, wherein n is >5; Head is an amino acid os
sequence of at least 3 amino acids an<l Tail is an amino acid
sequence ofat least 3 amino acids.
4
The Head and Thil sequences of a biolubricant substance
comprise at least 3 amino acids, preferably at lcast 4 amino
acids. The upper limit is typically about lGl2 residucs. The
length of the Tail and Head can be the samc or it can be
different. In one embodiment, the Head sequcncc has alcngth
of 3-5 amino acids. Preferred amino acids includc non-
charged amino acids, such as aliphatic residucs like Gly, Val,
Ala. Also preferred are Pro and Trp. In a spcciÍic aspect, the
Tail sequence comprises about 3-6 amino acids selectcd from
the group consisting of Gly, Ala, Val, Trp and Pro. For
example, the Head sequence is GAGP (SEQ lD NO: 8). As
another example, the Tail sequence is GCWP (SEQ lD N0:
9).
To facilitate isolation of a biolubricant substance, it mav
contain a protein tag sequence allowing for afÍinity puriíici-
tion of the substance. The tag sequence may be part of thc
Head or Tail sequence. Alternatively, it can be present within
the supercharged "core" of the substance. Protein affinity tag
sequences are known in the aÍ.
A preferred protein tag is the polyhistidine-tag, which is an
amino acid motif in proteins that consists ol' at lcast six
histidine (His) residues, often at the N- or C-terminus ol'thc
protein. It is also known as hexa histidine-tag, 6xHis-tag, and
by the trademarked name His-tag. Polyhistidine-tags are
often used for affinity purification of polyhistidine-tagged
recombinant proteins express ed in Esche ric hia <:o li and. other
prokaryotic expression systems. Affinity purilication using a
polyhistidine-tag usually results in relativcly pure protein
when the recombinant protein is expressed in prokaryotic
organisms. Bacterial cells are harvested via centrifugation
and the resulting cell pellet lysed either by physical means or
by means of detergents and enzymes such as lysozyme. At
this stage raw lysate contains the recombinant protein among
many other proteins originating from the bactcrial host. This
mixture is incubated with an affinity resin containing bound
bivalent nickel or cobalt ions, which are available commcÍ-
cially in different varieties. Nickel and cobalt have similar
propeÍties and as they are adjacent period 4 trzrnsition metáls
((v. iron triad)). These resins are generally sepharose/agarose
t'unctionalised with a chelatoq such as iminodiacetic acid
(Ni2*-lDA) and nitrilotriaceric acid (Ni2*-NTA) for nickel
and carboxylmethylaspartate (Co2*-CMA) for cobalt, which
the polyhistidine-tag binds with micromolar affinity. The
resin is then washed with phosphate buffer to rcmove proteins
that do not specifically interact with the cobalt or nickel ion.
Washing efficiency can be improved by the addition of 20
mM imidazole (proteins are usually eluted with l -50-3fi) mM
imidazole). Cenerally nickel-based resins havc higher bind-
ing capacity, while cobalGbased resins oflbr the highest
purity. The purity and amount of protein can bc assesscd by
SDS-PAGE and Western blotting.
In one cmbodiment, the Tail or Head sequcnce of a biolu-
bricant contains a polyhistidinc tag. Preferably, thc His-tag is
located at the C- or N-terminus. For example, the Tail
sequence i s GCWPH' (SEQ ID NO: I 0). As anorhcr example,
the Head sequencc is H.,GAGP (SEQ ID NO: I l ). The skilled
person will be able to design other variants of affinity-tag
containing biolubricant peptides.
As said, a biolubricant substance according to thc invention
is suitably prcpared by recombinant techniqucs using a suit-
able host cell that is provided with a nucleic acid cncoding the
substance. Hcnce, the invention also providcs an isolated
nuclcic acid scquence cncoding a (linear) polypcptide biolu-
bricant substance of thc invention. Also cncompasscd are
expression vectors and other types of genctic carriers com-
prising an isolatcd nuclcic acid of the invontion. Thc nucle-

























further dry mouth alleviating componen(s). For examplc, it
allows fbr the treatment of patients undt:rgoing radiothcrapy_
particularly to the mouth, oropharynx, or neck area, who may
expericnce dry mouth that results Íiom damage to the salivary
s glands.
The oral carc composition comprises an orally acceptable
vehiclc. Any suitablc orally acceptable vehicle can bc used,
such as those described in U.S. par. No. 4,994.220 titlcd
clinical applications.
over, preferably the humectant comprises propylene glycol,
s which can help to solubilize the biolubricant substancc. The
remaindcr of the humectant is preferably glyccrine ancl/or
sorbitol an<Vor xylitol. Water is present ypically in amount of
at least 3o/o by weight: and glycerine and/or sorbitol and/or
xylitol typically total 6.5Vo to 75Vo by weight of the oral
0 preparation, more typically 10To to75Vo, and, togethcr with
the solubilizing humectant, the essential humcctant compo_
nents typically amount to 7Vo Io gOVo by weight of the oral
preparation. Ref-erence hereto to soÍbitol refers to the matcrial
typically as available commercially in 70Vo aqueous solu_
5 tions.
A humectant, such as glycerine, sorbitol, xylitol, propylcne
glycol, othanol and mixtures thereof may be present in an
amount of l0 to 30o/oby weight. The oral carc composition
ggTqtjT-l l]e^ast one repeat of the cationic repeat scquence may containwatcr at5và rc3{Eoby wcight. Liquid dentiÍriccs(GKCVPXSEQ ID No: I )m' wherein 3<mcl b. the ikilled :o typícally contain Sovo to B5Vo of íaterlmay conlain o.5o/o Lopcrson will understand that numerous otherbranched variants ióct Ai weight of non-toxic alcohol and may also contain
can bc madc which satisfy the overall requirement that the 10o/o tá 40uí by weight of humectant, such as glyccrinc,biolubricant substance.ontains a total amóunt of at lcast 40 sorbitol, and./or xylitol. Sorbitol Íefèrs to thc material typi_positivcfy charged residues. cally available commercially inle% aqueous olutions.Also provided herein is a composition comprising a biolubri- ts Às another example, the tomposition is an ocular carc or
emt-substance according to.the invention and a pharmaceu- ophthalmic composition formulated for topical administra-tically acceptable carrier, diluent or excipient. TÈc composi- tiàn of a biolubricant substanco of the invention to the cyc.l'ion oÍ'tho invention can contain an amount of biolubricant Such composition is suitably uscd for the trcatment or prc-
substancc that can vary within a wide range, but always at vention of dry eye syndrome. The normal tear film is a rcla-therapcutically effectivc amounts. .10 tively stable,ihín fiím composcd of a superficial lipid layorIn this invention a "therapeutically effbctive amount" is and án aqueous layer intermixed with a mucus gel 1ayer whichdcfincd as the amount ofa biolubricant sufficient to cau.se an is partialiy adherent to the comeal and conjunctival surlaccincrcasc in biolubrication of a bodily cavity, in particular in 
"pitt"liuá. 
Natural tear film is important for the lubricationtcaring, vaginal secretion or salivary secretion in a patient. and maintenance ofthe refractive zurface ofthc eye. Dry cyeThercforc, thc composition of the invention can contain_ an +5 syndromc is a complex disease characterized by a dysfunc-amountof biolubricantsubstancerangingfrom0.l to2,000 t ionofoneormorecomponentsofthetearf i lm, lóadingtothe
mg' prcÍbrably within the ran^g^e Íïom 0.5 to -500 mg and, even loss of tcar film stability, a hyperosmotic shift in the tear íilm
morc prcÍ-orably, from I to 200 mg. Appropriate doscs of the osmotic balance, ana/oi an inàoequate amount of fluid on the
ocular surface. This is characterized by rapid break_up ofthe
tear film and numerous symptoms, including buming/sting_
ing, foreign bo<Iy sensation, itching, and photophobià.
Treatments used to treat xherophtalmia include corticos_
teroids which may be eff'ective in early stages of the disease,
vifamin A supplements and pilocarpine which is a drug that
increases tear production. Among improve dryness prepara_
tions (artificial tcars) solutions hypromellose and carbomer
gels which are applied to the conjunctiva are uscd. Howcver,
these troatments have clcar limitations regarding its eÍïicacy
and toxicity. Thcrefore, there is a nccd to providc ncw
improvcd trcatments Íbr xherophtalmia.
It has now becn discovered that a biolubricant substancc of
Inonc cmb<xliment, the composition is an oral care compo- 65
sition that allcviates dry mouth comprising a biolubricant

















traditional formulation the presence of biolubricant may
cause recruitment of PRG4 molecules, giving rise to betteÍ
lubrication. A formulations comprising a biolubricant as
herein disclosed is not only expected to Íecruit PRG4 but also
to lubricate the cornea-eyelid jnterface by synergistically
interacting with hyaluronic acid, a well known mechanism in
the field of cartilage lubrication. See Das ct al. (Biomacro-
molecules, 201 3, I 4(5), 1669-1677).
Compositions may be used to treat dry eye, or to diagnose,
cure, mitigate, treat, or prevent dry eye syndrome in man or
other animals. The formulations are sterile, buffered, oil and
waler emulsion artificial tear products formulated for the
relief of ocular surface irritation and symptoms of dryness.
Also provided is a method of treating, diagnosing, curing,
mitigating or preventing dry eye syndrome comprising
administering an effective amount of an ophthalmic compo-
sition according to the invention to an eye ofa man or other
animal in need thereof.
An ocular care composition typically comprises oph-
thalmically acceptable liquids. An ophthalmically acceptable
liquid includes a liquid formulated that is tolerable to a patient
for topical ophthalmic use. Additionally, an ophthalmically
acceptóle liquid could either be packaged for single use, or
for multiple uses containing a preservative to prevent con-
tamination. For ophthalmic application, solutions or medica-
ments may be prepared using a physiological saline solution
as a major vehicle. Ophthalmic solutions may be maintained
at a comfortable pH with an appropriate buffer system. The
lbrmulations may also contain conventional, pharmaceuti-
cally acceptable preservatives, stabilizers and surfactants.
An ophthalmically acceptable liquid may include further
demulcents or film forming materials. Examples of demul-
cents may include, but are not limited to polymers such as
polyvinyl alcohol, povidone, hydroxypropyl methyl cellu-
lose, poloxamers, carboxymethyl cellulose, hydroxyethyl
cellulose, acrylates; surfactants such as polyoxyethylene (80)
sorbitan monooleate and glycerin. The amount of demulcent
may vary. In some embodiments, the amount of any demul-
cent such as those listed above may be fiom about 0.1 7o w/w
toabout2lo wlw, orfrom aboutO.3Vo wlw toabout0.TVowlw,
or from about0.3%o Ww to about 0.5% wlw, or about 0.57o
w/w.
An ophthalmically acceptable liquid may include a buffer.
The buffer may vary, and may include any weak conjugate
acid-base pair suitable for maintaining a desirable pH range.
Examples include, but are not limited to, acetate buffers,
citrate buffers, phosphate bufiers, borate buffers, or a combi-
nation thereof. Acids or bases may be used to adjust the pH of
these formulations as needed. The amount ofbuffer used may
vary. In some embodiments, the buffer may have a concen-
tration in a range of óout I nM to about 100 mM. The pH of
a buffered solution may be increased by the addition of
sodium hydroxide or another base, or decreased by the addi-
tion of hydrochloric acid or another acid. In some embodi-
ments, the pH of acomposition may be from about 7 to about
7.5, or from about7.2 to about 7.4, or about7.3.
An ophthalmically acceptable liquid may include a preser-
vative. The preservative may vary, and may include any com-
pound or substance suitable for preventing microbial con-
tamination in an ophthalmic liquid subject to multiple uses
from the same container. heservatives that may be used in the
pharmaceutical compositions disclosed herein include, but
are not limited to, cationic preservatives such as quaternary
ammonium compounds including benzalkonium chloride,
polyquad, and the like; guanidine-based preservatives includ-
ing polyhexamethylene bi guanide (PHMI]), chlorhexidine,
and the like; chlorobutanol; mercury prcservatives such as
us 9,334,31282
thimerosal, phenylmercuric acetate and phcnylmercuric
nitrate; and oxidizing preservatives such as stabilized oxy-
chloro complexes (e.g. Purite@). Purite@ is a registercd
trademark of Allergan, Inc. In some emkrdiments, thc
5 amount of preservative in the liquid may bc tiom akrut
O.NOlVo w/w to óout 254o wlw, or from about 0.002% w/w
to about O.05% wlw, or from about 0.0057o Ww to aklut
O.O27o wlw, or about O.ïlVo wlw.
An ophthalmically acceptable liquid may include a surfac-
rn tant. The surfactant may vary, and may includc any compound'" that is surface active or can form micelles. A surfactant may
be used for assisting in dissolving an excipient or an activc
agent, dispersing a solid or liquid in a composition, enhancing
wetting, modifying drop size, stabilizing an cmulsion, or a
number ofother purposes. Useful surfactants include, but arc
l5 not limited to, surfactants of the following cla.sses: alcohols;
amine oxides; block polymers; carboxylated alcohol or alky-
lphenol ethoxylates; carboxylic acids/fatty acids; cthoxylatcd
alcohols; ethoxylated alkylphenols; ethoxylated arylphenols;
ethoxylated fatty acids; ethoxylated fatty esters or oils (ani-
zo mal and vegetable); fatty esters; fatty acid methyl ester
ethoxylates; glycerol esters; glycol esters; lanolin-based
derivatives; lecithin and lecithin derivatives; lignin and lignin
derivatives; methyl esters; monoglycerides and derivativcs;
polyethylene glycols; polymeric surfactants; propoxylated
25 and ethoxylated fatty acids, alcohols, or alkyl phenols; pro-
tei n-based surfactants ; sarcosi ne derivatives; sorbi tan deriva-
tives; sucrose and glucose esters and dcrivatives. In somc
embodiments, the surfactant may include polyothylenc gly-
cof (15)-hydroxystearate (CAS Number 7O142-346, avail-
"^ 
able as Solutol HS I 5@ from BASF), polyoxycthylene-poly-
" oxypropylene block copolymer (CAS No. 9003-ll-6,
available as Pluronic@ F-68 from BASF), polyoxyethylene
40 stearate (POBI,O stearate), polysorbate 80 or polyoxyeth-
ylene (80) sorbitan monooleate (CAS No.9005-6-5-6), sorbi-
tane monostearate (CAS No. 1338-4t -6, available Íu Spall'tv
35 60 from Croda Intemational PLC), polyoxyethylenglyccrol-
triricinoleat 35 (CAS No. 61791-12-6, availóle as Crcmo-
phor EL@ from BASF). The amount of surfactant may vary.
In some embodiments, the amount of any surfactant such as
those listed above may be from about 0.0017o w/w to about
ao 5Vo wlw, or from about0.lVo Ww to about 2wlw Vo, or from
ahout0.3%o to about0.1Vo, or from about0.3%o w/w to about
0.57owlw,orfrom about0.l To w/w to about I o/o w/w, orabout
0.5Vo wlw.
The invention also provides a method for treating or pre-
45 venting a condition associated with impaired lubrication of a
bodily cavity, comprising administering to a subject in need
thereof a therapeutically effective amount of a biolubrícant
substance or a composition according to the invention. For
example, the bodily cavity is the oral, ocular or vaginal cavity.
50 Thus, in one embodiment the condition is sclected from
xerostomia, xerophthalmia, Atrophic Vaginitis (vaginal dry-
ncss) and Sjógren's syndrome. The subject is preferably a
mammal, more preferably a human. The invcntion therefore
also encompasses veterinary applications of a supercharged
5s biolubricant substance.
LEGENDS TO THE FICURES
FIG. l. Influence of adsorption of recombinant cationic
eo SUPs and renewed exposure to saliva on thc softness of
salivary conditioning films. (a, b, c) Examples of the QCM-[)
response as a function of time to protein adsorption from
saliva on Au-coated quartz crystal surfacos, subsequcnt
adsorption of cationic recombinant SUPs (2 min) and
ó5 rcnewed exposure to salivary proteins, expresrcd as changcs
in third harmonic frequency (Àf3, thick line) and dissipation





adsorbed films: a) buffer/no recombinant SUP adsorption; b)
adsorption of recombinant K36 and c) adsorption of recom-
binant K72. (d) Structural softness of salivary conditioning
films aftcr bulïer treatment or recombinant cationic SUP
adsorption i. e. treated SCF and after renewed exposure to s
saliva i.c. sccondary SCF (S-SCF). Error bars represent the
standard dcviation over five independent measurements. Sta-
tistically significant (p<0.05, two tailed Studenr t-tcst) diff'er-
ences in softness of films with adsorbed K36 or K72 with
respect to control films are indicated by *. Significant differ- 
,^
ences in soÍtness between films with adsorbed K72 and K36 '"
are indicated by #.
FIG. 2. Influence of adsorption of recombinant cationic
SUPs and rcnewed exposure to saliva on the friction forces,
repulsivc force upon approach and glycosylation of salivary
conditioning Íilms. (a, b) Friction force as a function of nor- l5
mal forcc during increasing (closed symbols) and decreasing
(open symbols) normal forces: a) bareAu-coated QCM crys-
tal and S-SCF without adsoóed recombinant cationic SUPs;
b) S-SCFs with adsorbed recombinant cationic SUPs K36 or
K72 arul after renewed exposure to salivary proteins. Error 20
bars reprcscnt standard deviations over 12 measurements. c)
Examplo of the repulsive force as a function of tip separation
distancc lbr bare Au-coated QCM crystals, S-SCF without
adsorbcd recombinant cationic SUPs and with adsoóed K36
or K72. The repulsive force range (D) for all adsoóed protein 25Íilms is calculated with respect to hard contact recorded on
bare Au-coated crystal surface (inset FIG. 2c). Error bars
rcprescnt standard deviations over 30 force curves. d) The
degrec of glycosylation (Vo Oglyco) for S-SCFs without
adsorbcd rccombinant cationic SUPs and with adsoóed K36 ^^
or K72, obtained from adecomposition of the Ol s photoelec- '"
tron peak in XPS. Error bars represent the standard deviations
overthroc indcpendent XPS measurements on separately pre-
pared samples. Statistically significant (p<0.05, two tailed
Student t-test) differences in repulsive force range (c) and
glycosylation (d) of S-SCF with K36 or K72 with respect to 3s
S-SCF in absence of adsorbed recombinant SUPs are indi-
caled by *. Differences in repulsive force range between
S-SCF with adsorbed K36 or K72 are indicated bv #.
FIG. 3. Architecture of SCFs after adsorption of recombi-
nant cationic SUPs with different numbers of positive charges +0
and rcnewcd exposure to saliva. a) Adsorbed salivary condi-
tioning film, showing glycosylated mucins adsorbed in loops
and trains over a layer of adsorbed densely packed low-
molecular weight proteins, including proline-rich proteins,
histatins and,lysozymes. b) Salivary conditioning films after o5
adsorption of K36 (left panel) and K72 (righr panel). Rccom-
binant cationic SUPs interact with the negatively charged
glycosylated mucins, causing collapse of the glycosylated
$tructuro t-hrough electrostatic interaction. In case of K72, not
all positivc charges engaged with the mucins and remain 
_^
available lbr further interaction (right panel). c) Salivary con- 'u
ditioning films with adsorbed cationic SUPs and after
renewcd cxposure to saliva. No mucins are recruited in the
prcsencc ol'adsorbed K36 (left panel), but remaining positive
charges in the film possessing adsorbed K72 recruit mainly
glycosylatcd mucins to form a soft mucinous layer over a 55
compact SCF (right panel).
DE'TAILED DESCRIPTION OF THE INVENTION
Example I
l)csign, Development and Characterization of
Cationic Biolubricant SUPs
Materials
All chcmicals were used as received without any further
ptrification. The pUCl g ctoning vector, restriction enzymes,
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and GeneJETlM Plasmid Miniprep kit were purchased Íiom
Fermentas (St. tron-Rot, Germany). Digested DNA frag-
ments were purified using QlAquick@ spin miniprep kits
from QIAGEN, Inc. (Valencia, Calif.). E. coli XLl-llluc
competent cclls for plasmid ampliÍication were purchascd
fiom Stratagene (La Jolla, Calif.). Oligonuclcotides for
sequencing wcre ordered Íiom Sigma-Aldrich (St. Louis,
Mo.). A-cyano-4-hydroxycinnamic acid and internal stan-
dards trypsinogen and enolase for mass spectrometry werc
purchased from LaserBio Labs (Sophia-Antipolis, Francc).
Ultrapure water, resistivity >18.2 MO.cm was used for all
experiments.
Gene C)ligomerization:
Integrity of DNA sequence was verified by sequencing of
coding and complementary DNA strand after each cloning
step (SequenceXS, Leiden, The Netherlands). SUP monomcr
gene SUP K9, encoding for the polypeptide [CVGVP(SEQ
ID NO: 2(GKGVPXSEQ ID NO: l)rl, was ordcred from
Entelechon (Regensburg, Germany) and was delivered in thc
pEN vector. As the recognition sites of restriction enzymclr
PflMI and Bgll had to be preserved, one valine rcsidue pcr tcn
pentapeptide repeats was incorporated instead of a lysine
residue during each oligomerization step. All cloning steps
were performed according to standard molecular biology
methods. SUP K9 was transfened into the standard cloning
vector pUCl9, digested with EcoRI and HinDIIL Genc oli-
gomerization was perfbrmed as dcscribed by Meyer and
Chilkoti.l2í'i Genes of correct length were identified by gct
electrophoresis following plasmid digestion with EcoRI and
HinDIII and sequencíng (ServiceXS, Leiden, The Nether-
lands).
Protein Expression and Purifi cation:
Genes coding for K36 and K72 were cloned into the
expression vectoÍ pET25b(+)-SfiIHis6 as described
before.l tEl Escherichia cotiBLR (DE3) (Novagen Inc., San
Diego, Calif.) were transformed with pET25b(+)-SfilHis6
containing the respective SUP genes. For protein production,
Terrific Broth medium (tB; 12 g/L tryptone, 24 gtLyeut
extrÍrct) enriched with phosphate bulTer (2.31 gL KH2PO4,
12.54 gL K2HPO4) and glycerol (4 mUL), and supple-
mented with 100 pglm|- ampicillin was inoculated with an
overnight starterculture to an initial optical density at 600 nm
(ODo.*,) of 0.1 and incubated a137" C. with orbital agitation
at 250 rpm until ODo,", reached 0.7. Cultures were shifted to
30" C., for additional l6 h. Cells were harvested by centrifu-
gation (7,000 g ,?-O min,4" C.), resuspended in lysis buffer ( I 0
mM TrisHCl, pH 8.0, 300 mM NaCl, 20 mM imidqzole) to an
ODo,", of 100 and disrupted with a constant cell disrupter
(Constant Systems Ltd., Northands, UK). Cell debris was
removed by centrifugation (4O,000 g, 90 min, 4" C.).
Polypeptides were purified from the supernatant under native
conditions by Ni-sepharose chromatography (GE Health-
care). Protein-containing fractions were dialyzed cxtensively
against ultrapure water. Purified polypeptides were frozcn in
liquid nitrogen, lyophilizrd and stored at -l7o C. until furthcr
use.
Protei n Characterization:
Concentrations of purified SUPs wcrc determined by mca-
suring absorbance at 280 nm on a SpcctraMax M2 (Moleculzr
Devices, Sunnyvale, Calif.). Protein purity was determincd
by sodium dodecyl sulfate polyacrylamide gel elcctrophorc-
sis (SDS-PAGE) on a 12Vo polyacrylamide gel according to
Laemmli.l2Tl Gels were stained with coomassie staining solu-
tion(4OVo methanol, lV:% glacial acetic acid, I g/L Brilliant
Blue R250). Photographs of the gcls weÍe taken with a LAS-
3000 Image Reader (Fuji Photo Film CmbH, DusseldorÍ',
Germany). Both K36 and K72 showcd reduced elcctro-
phoretic mobility compared to a commercial molecular
us 9,334,312B2
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weight standard, a well-known phenomenon for elastin-like
pnlypeptides.l%'t8l Mass spectrometric analysis was per-
formed using a 4800 MALDI-TOF/TOF Analyzer (Applied
Biosystems, Foster City, Calif., USA) in the linear positive
mode. The protein samples were mixed 1 : I v/v with a recrys- 5
tal liz.ed a-cy ano-4-hydroxycinnamic acid matrix ( I 0 mg/ml
in 5O9o acetonitrile and 0.7o/o trifluoro acetic acid, LaserBio
Labs). Mass spectra were analyzed and calibrated internally
with the Data Explorer software, version 4.9 (Applied Bio-
systems, Foster City, Calif., USA). Trypsinogen (MW=23, t0
980) and enolase (MW-46,672) were used as calibration
standards for K3ó (expected MW=18,888) and K72 (ex-
pected MW=36,3.l 3), respectively.
Saliva Collection:
Salivafrom twenty healthy volunteers ( l0men, l0women, t5
average age 3018 years) was collected into ice-chilled cups
after stimulation of flow by chewing Parafilm@. Volunteers
gave their informed consent to saliva donation, in agreement
with the suidelines setoutbv the Medical-Ethical-Committee
at the University-Medical-Center-Groningen, The Nether-
lands. After saliva was pooled and centrifuged at 12,000 g, I -5
min, 4" C., phenylmethylsulfonylfluoride was added to a
concentÍation of I mM as a protease-inhibitor. Thc solution
was again centrifuged, dialyzed for 24 h,4o C. against dem-
ineralized water, and freeze-dried for storage. Lyophilized zs
st<rck was prepared by mixing freeze-dried material originat-
ing lïom 2 L ofsaliva. Reconstituted salivawas prepared from
thc lyophilized stock by dissolution of 1.5 mglml- in buffer (2
mM potassium phosphate, I mM CaCIr, 50 mM KCl, pH
6.8).
Quartz Crystal Microbalance with Dissipation Monitoring:
Structural softness and formation kinetics of SCFs were
studied using a QCM-D device, model Q-sense E4 (Q-sense,
Cothenburg, Sweden). Au-coated quartz crystals witb 5 MHz
werc used as substrata. Before each experiment, crystals were 35
cleaned by l0 min UV/ozone treatment, followed by immer-
sion into a 3 : I : I mixture of ultÍapure-water, NH. and HzO z ^ t
70" C. for l0 min, drying with N, and another UV/ozone
tÍcatment. QCM-D chamber is disc-shaped with the inlet and
outlet facing the crystal surface. The chamber was perfused +0
with buffer by peristaltic pump (lsmatec SA, Glattbrugg,
Switzerland), when stable base lines for both frequency and
dissipation at third harmonics were achieved, saliva was
introduced. Saliva was perfused through the chamber at 25"
C.lor 2 h, flow rate of 50 plJmin, corresponding with a shear 45
rate of 3 s-' after which, the chamber was pert'used with
bufferor0.057oWv of SUPfor2 min and followed by another
2 h of salivary flow to form a secondary SCF denoted as
S-SCF. In between steps, the chamber was perfused with
buffer for l -5 min or till a stable frequency shift of less than 2 50
Hz over l0 min was observed. The shear rate in thc QCM-D
represents a low oral salivary flow.l2elFrequency and dissi-
pation were measured real-time during perfusion. After
experiments, crystals were removed from the QCM-D and
immediately used for further experiments. 55
Colloidal Probe Atomic Force Microscopy:
Friction tbrce, surface topography and repulsive force
range toward a colloidal AFM probel3ol were measured in
buflbr with an AFM (Nanoscope IV Dimcnsion'rM3l00)
equipped with a Dimension Hybrid XYZ SPM scanner head oo
(Veeco, N.Y., USA) on the differently adsorbed SCFs. Rect-
angular, tipless cantilevers were calibrated for their torsional
and normal stiffness using AFM Tunc lT v2.5 software.l3rl
Thc normal stiffness (K^) was between 0.01-0.(X N/m zrnd the
torsional stiffness (K,) bctween 2-4 ltre Nm/rad. Subse- os
qucntly, a silica-particlc of 4.74 pm diametcr (d) (Bangs
laboratories, Fishers, Ind., USA) was glucd to a cantilever
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with an epoxy glue (Pattex, Brussels, Belgium). Thc deflec-
tion sensitivity (a) of the colloidal probe was recorded at a
constant compliance with bare crystal in buffcr to calculatc
the normal force (F") applied using
F,,=LV,*a*K^ (2)
where ÀV, is the voltage output from the AFM photodiode
due to normal deflection of the colloidal probc. Thc torsional
stiffncss and geometrical parameters of the probc were used
to calculate the friction force (Fr)lre' 321 according to
(3)
where t is the thickness of the cantilever, 6 is the torsional
detector sensitivity of the AFM and ÁVr_ corresponds to the
voltage output from the AFM photodiode due to lateral
deflection of the probe. Lateral deflection was observed at a
scanning angle of 90 degrees over a scan area of 5x-5 pm2 and
a scanning frequency of 1 Hz. The colloidal probe was incre-
mentally loaded and unloaded up to a normal forcc of 35 nN.
At each normal force, l0 friction loops were recorded to yield
the average friction force. Repulsive forcedistancc curves
between a colloidal probe and the films werc ohtained at a
trigger threshold of 10 nN and an approach and rctraction
velocity of l0 pm/s. The repulsive force range (D) was deter-
mined at a point where colloidal tip starts expericncing the
repulsive force >l nN between the two interacting surfaces.
X-Ray Photoelectron Spectroscopy:
Glycosylation of the adsorbed SCFs was detcrmined by
using XPS (S-probe, Surface Science Instruments, Mcluntain
View Calif., USA). Films adsorbed on Au-coatcd quaÍz
crystals as removed from the QCM-D, were dricd in the
pre-vacuum chamber of the XPS, and then subjccted to a
vacuum of l0-7 Pa. X-rays (10 kY 22 mA, spot size 250x
I 000 pm), were produced using an aluminum anodc. Scans in
the binding energy range of l-1100 eV were made at low
resolution (pass energy l-50 eV). The area under cach peak
was used to yield elemental surface concentrations for C, O,
N, and Au after correction with sensitivity factors provided by
the manufacturer. The O," peak was split into thrcc compo-
nents for oxygen involved in amide groups (C-_=O-N; 531.3
eV), carboxyl groups (C--O-H;532.7 eV) and oxygen aris-
ing from the crystal. Accordingly, the fraction of thc Or- peak
at 532.7 eY (7o Or.r.r) was used to calculate the amount of
oxygen involved in glycosylated moieties (o/o íJ16,,,) and
amides (7o Oon,i,u*).
%Or4,,,=(ko5az1*qoot,,í,,t (4)
%t O,u,;a,'=9o O5111*9o Or,., (5)
whereTo Ouro,is the total percentage ofoxygcn.
Results
Tlvo exemplary SUPs with the amino acid scquences
GAGP(SEQ lD No: 8)[(GVGVPXSEQ ID NO: 2XcKcVP)
(SEQ ID NO: l),I.CWPH6(SEQ ID NO: l0) (K36) and
GAGP(SEQ lD No: 8)[(GVGVPXSEQ ID NO: 2XcKcVP)
(SEQ ll) NO: l)'I"GWPHó(SEQ ID NO: l0) (K72) were
labricated by recombinant protein expression in lischerichia
r:oli. The gcne sequcnce and respcctive aamino acid scquence
ol the monomer are shown below.
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due to long-range repulsive forces between S_SCFs and thc
EcoRr prlMr 
(sEQ rD No: 12) approaching colloidat probe. The repulsivc lbrcc rangc aris-
A AT r cÀr Arc ccc-c!\c ccc crc_ccr crr ccc ccc ÀÀA ing Íiom the S-SCFs increased with the number of positive
c v 
-è 
v P G K charges after adsorption of recombinant cationic SUPs (FIG.
c.cr crr ccc ccr ÀÀÀ ccr crc cce ccc AAÀ ccr crr 
, 
?r).Jgg1".morc insight into the structural composition of
c  v  p  e  K  G v  p  c  K  o  
'u '  theS-SCFs,XPSwasapp l ied tomcasure thec lcgreeofg ly -
cosylation, which is relatcd to the water contcnt of the surface
ccr GGr ÀÀÀ GGr GrG ccc GGr ÀÀÀ GGr GTG ccc ccr (FIG. LD. Glycosylation in the S-SCFs with no a{sortrcdP G K G v P G K G v P G 
.^ Àup*uÀlrnt.to5.8t0.SToandincrcaseswiththemolccular
AÀA ccr crÀ ccÀ c'cr ÀAÀ ccr crr ccc ccr AÀÀ ccc l0 weightof theadsorbedSUPs to6.9t{).3Voand7.?-fl.6o/oin
K c v p c K c v p c K G SCFswithK3óandKT2,respectivcly.
crr ccc crr ÀÀÀ c.cr crq,lqc Hà'"*.," Hindrrr *"ï'"""ïiHÏjj}ï'ïffirï:Ïi.1,ïtffiSi:ïïï::1ïi;
v p G K G v n l. their structural softness, i.e. increase thcir rigidity. SUPs car-
Thc gcne length was verified using gel electrophoresi, yJlï^T:: positive charges create more rigid Íilms, and morc(datanushown)lrypicaryieldswere4í*gtrcolunïioË :J^:l:lil^J::ruit salivarv protcins to form a scF with a(K72) of purified protein per literof culture]p".ináo porvp"pl :::-":9]:o:'- structurc and highcr dcgrce of glycosylation,
tides woie separated on a sDS-pAce g"r. vus, 
"rËcil 
^^ F::.":11i9^a 
longcr repulsive forco rangc and morc stable,
yieldcd sharp peaks for both variants i.e. K36 uno xiíil"j 20 loY friction' Patients with oral dryness symptoms havc
ihei, ,"rses'*ere 18,932t20Da for K36 ana ro,ttci'oïi ::1",i :ilt"av flow rates, but narurailv occurring salivzry
ror Kl2.rhe rormation or SCFs on gord lauy 
"out"o qliul,tl Hij:ï,ïi.ïïïïËï1,'*ï;ililïfJ;:*i,.1ï,1ï"iffi:crystals and the effects of their exposure to recombinanj K?.6 ;;;;;i";;:r"combinant, cationic SUps to improve scvcraland K72 or buffer' followed by renewed adsorption of sali- 
,r il;"ï;;"cruciar for cffective biolubrication. our approachvary proteins, were observed real{ime in the QCM-D, as ;ó;;;;;,;;;roundbreakingstratcgylbrartificial biolubrica_prescntcd in FIG. la-c.
Exp.sure oran existing SCF to buffer (FrG. la) yierded I l1i,ï;Ji"ïi:;t"i:t';ffilÏ f,ffi,'1."ïi::,ilir:*ïï,:lïsmall changc in the oscillating sensor frequency (Àf.) and of principle was obtained for oral lubrication the most chal-gryqlign (ÁD.), whereas exposure to K36 (FrG. lb) and :o lenging Ënvironment for biolubrication, but similar recruit-K72 (FIG. lc) solutions caused significant decreases in ^f" meit Àechanisms can be applied in other parts of the human
and ÀD" that were largcst for K72. Subsequent removal ofthà body (e.Í. ocular or vaginaí èavity) m well.
Ptot"in solution by pcrfusing the QCM-D chamber with SbFiscomposedoiglycosytaióo,high-molecularwcightbufÍ'er indicated a structural decrease in the softness of the mucins (0.25 to 20 MDai ihat ádsorb in l-oops and trains (withSCFs,cxpressedastheratio(AD"/Àf.).Again,thiseffectwas 3s a molecular aspect ratio of up to f /rUdyizïila1ffiji"5;larger after exposure to K72 solution than after exposure to provide a scaffold to hold and retain water molecules at theK36 solution (FlC. 1d). Renewed salivary exposure over the iurface, while adsorbed smaller proteins like proline-richSCFswasinitiatedimmediatelyaftertreatmentwithbufferor proteins, hístatins, lysozymes, and amylases may be found
recombinant protein solutions to form S-SCFs (FIG. |a-c) undemeath the loops uná b"t*een the trains CíC. fol:rllbecau-sc such experimental conditions reflect best the in vivo +0 Based on the measurements presented above, we sugge st a
situation of immediate reflow of saliva in the oral cavitv.
Renewcd pcrfusion of rhe QCM-D chamber with sativa did
not affect the structural softness of the S-SCF with onlv buffer
without rccombinant SUPs (FIG. ld), but S-SCF wíh K36
solution became softer again to a level comparable to S-SCF +:
without recombinant SUPs. The S-SCFs withK72, however,
were signiÍicantly (p<0.05, two tailed Student t-test) softer
rhan S-SCFs with K36.
In a ncxt step, the lubrication properties of the SUp-modi-
pared with K36 neutralizes negative charges in the SCfl but
importantly not all positive charges of K72 are engaged in
interaction with negative charges in the SCF and positive
charges of adsorbed K72 remain available for further inter_
than on Au-coated crystals with a COF of 0.19, and linearity 5s actioi with negative charges. This can be concluded from zetabroke down at normal forces above 14 nN. Note that the potential meaiurements (data not shown), showing more
negativc Íïiction forces at a normal force of 1.5 nN represent positive charge on SCFs exposed,toKj2than on K36-trcatcd
thc known limitation ol'AFM to measure very low friction ànd untreateà SCFs (data not shown). Thus uncompensatedforces'lr"l However, mcasurements on S-SCFi with recom- positivesurfacechargesofadsorbcd(T2onaSCFcantriggcr
binant SUPs clearly showed lower triction forces (FIG. 2b). a iurther recruitment of negatively charged glycosyt"ó4
Linearity corresponding to a COF of 0.08 persisted up_ to.a mucins during rcnewed exposurc io salivà 6tc. fai tgtrt
normal íorce of 20 nN for K36, while lincarity (R2=0.94) panel), resultiág in a solter irighly hyclrated over-layer (FíC.
corrcsponding to an extremely low COF of 0.06 existed over 3c). This recruitment proccss-rejuvónatos the film,'as it can
the entiro range of normal forces applied for K72-modified bind to more water moiecules. This is onc critical step boyond
íilms,indicativeofahighstructuralintegrity.Contactofthe ó5 simply restoring the film structure, as observe6 ln SCps
AFM colloidal probe with theAu-coatcd quartz crystal (FIG. formecl after rcflow of saliva over K36-treated and buffcr-
2c) shows a hard matcrial compared with the softer S-SCFs treated SCFs.
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The rigid and hydrated S-SCF, modiÍied with adsorbed
KT2andafter renewcd exposure to saliva, shows low friction
forces and a structural integrity that is not compromised at
higher contact pressures, in contrast to films containing K36
or untreated films. The breakdown of structural integrity in
these latteÍ films can be seen Íiom the discontinuity in the
linearity of friction force against the normal Íbrce.l23'2al In
order to determine the mechanical strength of the S-SCFs, we
have applied Von Mises distortion energy criterion that relates
the normal force at which the discontinuity arises (fr.) to the
yield strength (or) o1'the filmql24'251 throuêh
I  l ^ (  3*  I t .  \2  I  3*  f ,  ) l ' ,  ( l )c v  =  
6 l z \ 2 4 -  R - . 6 )  " l z - ,  -  n . d ) l
where R,, is the radius of the colloidal probe (2.37 pm), 6 is
the elastic displacement of the film determined from a Hert-
zian fit to the force-distance curves as obtained by colloidal
probe AFM and fris the friction fbrce at Í).. Accordingly, yield
strength for S-SCF in absence of recombinant cationic SUPs
is 80t12 kPa, increasing to 102+8 kPa in the presence of
adsorbed K3ó. In contrast, no discontinuity in the linearity of
friction force against the normal force was observed forK72-
treated films within the range of normal forces applied, indi-
cating that the yield strength of S-SCFs in presence of K72
exceeds 102 kPa. This increase in the yield strength can be
attributed to improved cohesive strength in the adsorbed
lilms, against the applied shear force.
In conclusion, an ideal biolubricanflike artificial saliva
should lubricate the oral surfaces and at the same time sustain
this lubrication for lasting benefits. Here we demonstrate that
non-toxic, recombinant cationic SUPs adsorb on SCFs to
recruit further glycosylated mucins from saliva, provided the
number of positive charges is sufficiently high. These
hydrated and rigid films improve interfacial lubrication and
maintain their structural integrity upon high contact pres-
sures. Current generations of artificial salivas are inadequate
to restore oral lubrication on a lasting basis. Cationic recom-
binant SUPs as additives, however, go even beyond restora-
tion to rejuvenation ofthc film, affording effective lubrication
under conditions of reduced availability of naturally occur-
ring proteins. On the basis of the cooperative layer-by-layer
mechanism laid out here, cationic protein polyelectrolytes
show gÍeat promise for restoring impaired biolubrication.
Example 2
Oral Composition Comprising SUP
A translucent oral composition e.g. for usc as artificial
saf iva composition comprising biolubricant peptide (0.057o
w/v) and optionally bovine submandibular Mucins (3.52o
w/v), and has a pH value of between 5 and 6.
Example 3
Ocular Composition Comprising SUP
A typical crcular composition includes the ingredients
listed below,
O.lVo wlw to about 27o wlw demulcent.:
Biolubricant peptide 0.05o/o wlv
Sodium Chloride: 0.47o wlv 6,5
Potassium Chloride 0.038
Polyquatemium- I 0.00001 -0.001
us 9,334,31282
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NaOH/HCI q.s. pH 7.4
Purified Water q.s. to 100.
Example 4
5
Use of SUP for Treating Dry Mouth
The composition of example 2 is used to trcat a patient with
dry mouth. The patient applied the composition oí'example 2
I 0 to an oral cavity, swished thoroughly for about. 30 seconds to
about one minute, then spit out the composition, and repeated
this application 2-3 rimes per day. The patient noticed relief
from (mitigation of) dry mouth and irritation. The patient
noticed a moist and a clean and refreshed Íècling within the
1.5 mouth. The patient also noticed that there was no burning
sensation noticed with application of the composition.
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INCORPORATTON OF SEQUENCE L|STTNC
_ 
Incorporatcd hcrein by refercncc in its entirety is the
Sequcncc Listing forthe applicarion. The Sequence Listing is
disclosed on a computer-readable ASCII text fite titled,
*subs_seq_list_294_432.txt", 
created on Apr. ZZ, 201 4. The
file is 9.64 kb in size.
I O
SEQIJENCE LISTING
<160> NUÈIBER OF SEQ ID NOS: 15
< 2 1 0 >  S E O  r D  N O  1
<21L> LENGTH:  5
<212> TYPE:  PRT
<213> ORGANISM:  Àr t i f  i c ia l  Sequence
<220> FEÀTURE:
<223> OTHER INFORMÀTION: building block biohÈricant
<400> SEQIJENCE:  1
GIy r,ys cly Val pro
1 5
<210> sEQ rD NO 2
<21.1.> LENGTH: 5
<2L2> TYPE:  PRT
<213> ORGÀNfSM:  Àr t i f  i c ia l  Sequence
<220> FÉATTJRE:
<223> OTIÍER INFORMATÍON: bui]ding btock of biolubricant
<400> SEQUENCE:  2
Gly Val c1y VaI Pro
1 q
<210> SEO rD NO 3
<211> LENGTH:  45
<212> TYPE:  PRT
<213> ORGANISM:  Àr t i f i c ia l  Sequence
<220> FEÀTTJRE:
<223> OTI{ER INFORMATION: bio}ubricant
<400> SEQUENCE: 3
GIy Lys Gly val pro c1y Lys
r 5
Lys cly val Pro cly Lys c1y
Gly val Pro cly Lys cly Val
3 5
GIy Val Pro cly Lys cly val pro c1y
1 0  1 5
Val Pro cly Lys Gly Val pro cty Lys
2 5  3 0
Pro Gly Lys cIy Val pro
4 0  4 5
<210> SEQ rD NO 4
<211> LENGTH:  5
< 2 1 2 >  T Y P E :  P R T
<213> ORGANISM:  Ar r i f  i c ia l  Sequence
<220> FEÀ?IJRE:
<223> OTHER INFORMÀTION:  bu i ld ing  b lock  e las t . in_1 ike  pro te in
<400> SEQUENCE:  4
Val Pro cly Val cty
1 5
<210> SEQ ID NO 5





<212> TYPE:  PRT
<213> oRGÀNISM:  Ar t i f i c ia l  sequence
<220> FF"ATITRE:
<223> OTHER INFORMÀTION:  mot i f  e laaÈin- l i ke  p ro te in
<400> SEQUENCE:  5
val Pro Gly Val Gly val Pro Gly VaL Gly val Pro Gly val G1y val
1 5 1 0 1 5
Pro Gly va1 Gly
. 2 0
<210> SEo rD NO 6
<211> LENGTII: 5
<212> TYPE:  PRT
<213> oRGANISM:  Àr t i f  i c ia l  sêquence
<220> FEÀTTJRE:
<223> OTHER INFORIIATION: caÈionic sequence
<400> SEQIIENCE: 5
cly Lys cly val Pro
< 2 1 0 >  s E Q  r D  N O  7
<2L1"> LENGTH: 6
<2L2> TYPE:  PRT
<21.3> ORGÀNISM:  ArÈ i f i c ia l  sequence
<220> FEÀTURE:
<223> OTHER INFORMATION: non-charged 6i1k-like uniE
<400> SEQITENCB: 7
c ly  A la  c ly  A la  GIy  Ser
<210> SEQ rD NO I
<211> LENGTH:  4
<212> TYPE:  PRT
<2L3> oRGÀNISM:  ÀrÈ i f  i c Ía l  sequence
<220> FEÀTIJRE:
<223> oTHER INFORMATION: head sequênce biolu.bricanÈ
<400> SEQIIENCE: 8
Gly ÀIa cly Pro
1
<210> SEQ ID NO 9
<211> LENGTH:  4
<212> TYPE:  PRT
<213> ORGÀNISM:  Ar t i f  i c ia l  Sequence
<220> FE,ATURE:
<223> oTHER INFoRMÀTIoN: tail sequence of biolubricant
<400> SEOIJENCE: 9
Gly GIy Trp Pro
1
<210> SEQ rD NO 10
<211> LENGTH:  10
<21-2> TYPE:  PRT
<213> ORGÀNISM:  Ar t i f i c ia l  Sequence
<220> FEÀTTJRE:
<223> OTHER INFoRMÀTION: EaiI aequence of biolubrÍcanÈ
<400> SEQUENCE:  10






< 2 1 0 >  S E Q  r D  N O  1 1
<21L> LENGTH:  10
<212> TYPE:  PRT
<213> ORGÀNISM:  Àr t i f  i c ia l  Sequence
<220> PEÀTURE:
<223> OTHER INFORMATION: head aequence biolubricant
<400> SEQI IENCET 11
His  H is  H is  H is  H is  H is  G ly  À ]a  G1y Pro
1  5  1 0
< 2 1 0 >  S E Q  r D  N O  1 2
<21L> LENGTH:  180
<21.2> TYPE:  DNÀ
<2L3> ORGÀNISM:  Àr t i f  i c ia l  Sequence
<220> FE,ATT]RE:
<223> OTHER INFORMATION: DNA codinq for monomer of biolubrucant
<220> FE,ATURE:
<22L> NÀME/KEY: CDS
< 2 2 2 >  L O C A T I O N :  ( 1 7 )  . .  ( 1 6 6 )
<400> SEQUENCE:  12
aatEcaÈaEg ggccac ggc gtg ggt gEt ccg ggc aaa
Gly VaI Gly Va1 Pro GIy Lyg
ggE gtg ccg ggc aaa gg! gtÈ cct ggt aaa ggE gEg ccg 99È aaa ggÈ
cly Val Pro G1y Lys Gly val Pro Gly IJys Gly val Pro Gly Lys Gly
1 5  2 0  2 5
gEg ccg ggÈ aaa ggt gta cca ggÈ aaa ggE gEÈ ccg ggÈ aaa ggc atE
Val Pro Gly Lys Gly val Pro GIy Lys GIy va] Pro Gly IJys Gly val
3 0  3 5  4 0
ccg gEC aaa ggt gtg cca ggcgggcEgg aaEa
Pro val LyB Gly val Pro
4 5 5 0
<210> SEO rD NO 13
<211> LENGTH:  50
<212> TYPE:  PRT
<21.3> ORGÀNISM: Artif icial Sequence
<220> FE,ÀTTJRE:
<223> OTHER INFORMÀTÍON: SynÈhegic ConsEruct
<400> SEQUENCE:  13
c1y va1 cly vat Pro G1y Lya GIy va1 Pro GIy LyE GIy val Pro GIy
1 5 L 0 1 5
Lys Gty val Pro Gly Lys Gly Val Pro Gly Lys Gly vaL Pro GIy Lys
2 0  2 5  3 0
cly vat Pro Gty Lys Gly va1 Pro Gly Lys Gly Val Pro val Lys Gly
3 5  4 0  4 5
Val Pro
5 0
<21-0> sEQ rD NO 14
<211> LENGTH:  213
<212> TYPE:  PRT
<213> ORGÀNISMT ArEificial SequeÍrce
<220> FEÀTURE:
<223> OTHER INFORIIATION: K36
<400> SEQUENCE:  14
GIy Ala Gty Pro GIy Va1 GIy val Pro GIy Lys Gly VaL Pro Gly Lys
1 5 1 0 1 5
Gly VaI Pro GIy Lys Gly val Pro Gly Lye Gly val Pro Gly Lys Gly
2 0  2 5  3 0
ggt gÈÈ ccg 99È aaa 52








val Pro Gly Lys Gly val Pro Gly LyÊ Gly ya1 pro GIy LyB Gly val
3 5  4 0  4 5
Pro GIy Ly6 GIy VaI Pro Gly Val Gly Val Pro GIy Lys Gly Val Pro
5 0  5 5  6 0
GIy lrys Gly val Pro GIy tys Gly val Pro Gly LyB Gly val Pro Gly
6 5  ' 7 0  1 5  8 0
Irys GIy vaL Pro GIy Lys Gly VaI Pro Gly Lys Gly val Pro Gly LyÉ
s 5  9 0  9 5
Gly Val Pro GIy Lys GIy Va1 Pro Gly Vat GIy val Pro Gly Lys G1y
1 - O O  1 0 5  1 1 0
val Pro GIy Lys GLy Val Pro G1y Lys G1y VaI pro GIy Lys Gly VaI
1 1 5  L 2 O  
' J - 2 5
Pro Gly Lys G1y val Pro GIy Lys Gly val Pro Gly Lys Gly val Pro
1 3 0  1 3 5  1 4 0
Gly Lys Gly va1 Pro Gly Lys Gly val Pro Gly va1 Gly va1 Pro Gly
1 4 5  1 5 0  1 5 5  1 6 0
Lys GIy Val Pro GIy LyB GIy Val Pro GIy Lys GLy val Pro Gly Lys
L 6 5  L 7 O  1 7 5
cly val Pro GIy Lys GIy val pro Gty Lys GIy va1 Pro G1y Lys Gly
1 8 0  1 8 5  1 9 0
val Pro GIy ÍJys GIy val Pro Gly Lys GIy val Pro Gly Trp Pro Hre
L95 200 205
Hia  H is  H is  H is  H is
2 t o
<210> sEQ rD NO 15
<211> LENGTH:  413
<212> TYPE:  PRT
<213> ORGANISM: ÀrEificial Sequence
<220> FE,ÀTTJRE:
<223> OTHER INFORMATION: K72
<400> SEQUENCE:  15
GIy Ala Gly Pto Gly VaI Gly Val
L
cly val Pro GlY
Pro GIy LYs G1Y Val Pro GlY I,Yg
t 0  l - 5
Lys Gly va1 Pro Gly Lys Gty va1 Pro Gly Lys GIy
2 5  3 0
Val Pro G1y Lye Gly val Pro Gly Lys Gly val Pro GIy Lys Gly Val
3 5  4 0  4 5
Pro cly Lys G1y val Pro Gly val Gly Val Pro Gly Lys G1y val Pro
5 0  5 5  6 0
GIy Lys Gly VaI Pro Gly L,ys GIy Val Pro Gly Lys GIy VaI Pro Gly
6 s  ' t o  7 5  8 0
Lys Gly vaf Pro Gly Lys GIy VaI Pro Gly Lys GIy Val Pro Gly LyB
8 5  9 0  9 s
Gly va1 Pro Gly LyB GIy val Pro GIy val Gty va] Pro Gly l 'ys Gly
1 o o  1 0 5  1 1 0
val Pro GIy Lys G1y vat Pro GIy IJys Gly val Pro G1y Lyê Gly val
1L5 r20  r25
Pro GIy Lys GIy val Pro Gty LyB Gly va1 Pro GLy Lys Gly val Pro
1 3 0  1 3 5  1 4 0
cly Lys Gly val Pro Gly Lys Gly val Pro Gly val GIy val Pro Gly
1 4 5  1 5 0  1 5 5  1 5 0
Lys Gly VaI Pro G1y LyÊ Gly Val Pro Gty Lys Gly Val Pro Gly LyB




Gly va1 Pro GIY LYs GIY va1 Pro
1 8 0
vaf  Pro  GIY LYs GIY va1 Pro  G1Y
2 0 4
Gly Lys GlY va1 Pro GlY LYS G1Y
1 8 5  1 9 0
Lys Gly val Pro GtY val G1Y va1
205
Pro Gfy Í,yE G1y val Pro Gly Lys Gly vaI Pro Gly Lys Gty Va1 Pro
2r5  22o
cly Lys Gly val Pro GLy Lys Gly Val Pro Gly Lys G1y va1 
Pro Gly
225 230 235 
240
Lys G1y val Pro GIy Lys Gly val Pro Gly Lys Gly val Pro Gly 
val
245 25o 255
c1y val Pro G1y Lys GIy val Pro G1y Lys Gly va1 Pro Gly Lys 
Gly
260 265 2 '7  0
val Pro G1y Lys G1y val Pro G1y Ly6 Gly val Pro Gly Lys G1y 
va1
2 1 5  2 8 0  2 s s
Pro Gfy Lys Gty val Pro G1y Lys G1y va1 Pro Gly Lys Gly val 
Pro
2 9 0  2 9 5  3 0 0
cly Va1 Gly Val Pro Gly Lys Gly val Pro Gly Lys GIy val Pro 
G1y
3  O - 5  3  1 0  3 1 5  
1 2 0
Lys Gly Va1 Pro Gly Lys Gly VaI Pro G1y Lys G1y va1 Pro Gly 
Lys
3 2 5  3 3 0  3 3 5
Gty Va1 Pro Gly Lys Gly va1 Pro Gly Lys GIy Val Pro G1y Lys 
Gly
3 4 0  3 4 5  3 5 0
val Pro G1y val Gty va1 Pro G1y Lys Gly val- Pro Gly Lys Gly 
Val
3 5 5  3 6 0  3 6 5
Pro Gly T,ys Gly Val Pro Gty Lys GIy VaI Pro GIy Lys Gly Val Pro
3 ? 0  3 ' 1 5  3 8 0
c1y Lys Gly val Pro G1y Lys Gly val Pro G1y Lys G1y val Pro GIy
3 8 ' 5  3 9 ó  3 9 s  
4 o o
Lys  GIy  va l  Pro  G1y Trp  Pro  H i6  H is  H is  H is  H is  H is
4 0 5  4 1 0
Tho invcntion claimcd is:
1. A protcinaceous biolubricant substance comprising the
sencral'lirrmula Head-(SEQ ID NO: l)(SEQ ID NO: 2)ol^-
Íail. whcrein
n  is  >5 ;
É"utt it * urnino acid sequence of 3 to l2 amino acids; and
Tail is an amino acid sequence of at least 3 amino acids'
2. Thc protcinaceous biólubricant substance according to
claim 1, whcrein n is >6.
3. Thc proteinaceous biolubricant substance according to
claim 1, whcrein Head is SEQ ID NO: 8'
4. Ttre proteinaceous biolubricant substance according to
claim 1, lbrther comprising a protein tag sequence allowing
lbr afïinity purification of the substance.
5. Thc proteinaceous biolubricant substance according to
claim 4, whcrein head or Tail comprises a His-tag'
6. Tho proteinaceous biolubricant substance according to
7, whcrein m is in the range of 2-10.
9. Thc branched biolubricant substancc according to claim
7, whr:rcin n is at least 5.
10. An isolated nucleic acid sequence cncoding a biolubri-
cant substance according to claim l'
11. An expression vector comprising an isolated nucleic
acid according to claim 10
12. A non-human hostcell comprising an expression vector
according to claim 11.
13. A composition comprising a biolubricant substance
according to claim 1, and a pharmaceutically acceptable car-
rier, dilucnt or exciPient.
14. A composition comprising a biolubricant substance
according to ilaim ? and a pharmaceutically acceptablc car-
50 rier, diluent or exciPient.
15. An oral care composition that alleviates dry mouth
comprising a proteinaceous biolubricant substance compfl s-
ing i(spQ ID No: 
.l)rln, 
wherein n is >5'
16. An oral care composition that alleviates dry mouth
55 comprising a proteinaceous biolubricant substance having a
degree of-n oi branching, each of thc.branchcs comprising
(SÉQ lO NO: 1)m wherein n times m is at least 40'
17. A method lbr treating or preventing a condition asso-
- ^  ciated with impaircd lubrication of a bodily cavity' compris-zu 
ing administcring to a subject in need thereof a therapreuti-
caÍy clTective amount of abiolubricant subsLance according
to claim 1.
lE. The method according to claim 17, whercin said bodily
ó5 cavity is the oral, ocular or vaginal cavity'










20. The method according to claim 17, wherein said con-
dition is xerostomia, xerophthalmia, Atrophic Vaginitis (vagi-
nal dryness) or Sjogren's syndrome.
21. A method for treating or preventing a condition asso-
ciated with impaired lubrication of a bodily cavity, compris-
ing administering to a subject in need thereof a therapeuti-
cally effective amount of a biolubricant substance according
to claim 7.
22.The method according to claim 21, wherein said bodily
cavity is the oral, ocular or vaginal cavity.
23. The method according toclaim 21, wherein said subject
is a mammal.
A-The rnethod according to claim 21, wherein said con-
dition is xerostomia, xerophthalmia, Atrophic Vaginitis (vagi-
nal dryness) or Sjogren's syndrome.
25. A method for treating or preventing a condition asso-
ciated with impaired lubrication of a bodily cavity, compris-
ing administering to a subject in need thereof a therapeuti-
cally effective amount of a composition comprising a
biolubricant substance according to claim 13.
us 9,334,31282
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2ó. The method according to claim 25, whcrein said bodily
cavity is the oral, ocular or vaginal cavity.
27. The method accoÍding to claim 25, wherein said subject
is a mammal.
5 ?Á. The method according to claim 25, wherein said con-
dition is xerostomia, xerophthalmia, Atrophic Vaginitis (vagi-
nal dryness) or Sjogren's syndrome.
29. A method for treating or preventing a condition asso-
ciated with impaired lubrication of a bodily cavity, compris-
to ing administering to a subject in need thercof a therapcuti-
cally effective amount of a biolubricant substance according
to claim 14.
30. The method according to claim 29, wherein said bodily
cavity is the oral, ocular or vaginal cavity.
l s 31. The method according to claim 29, whercin said subject
is a mammal.
32. The method according to claim 29, wherein said con-
dition is xerostomia, xerophthalmia, Atrophic Vaginitis (vagi-
nal dryness) or Sjogren's syndrome.
